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Abstract
Background: Potentially inappropriate prescribing in older people is common in primary care and can result in
increased morbidity, adverse drug events, hospitalizations and mortality. In Ireland, 36% of those aged 70 years or
over received at least one potentially inappropriate medication, with an associated expenditure of over €45 million.
The main objective of this study is to determine the effectiveness and acceptability of a complex, multifaceted
intervention in reducing the level of potentially inappropriate prescribing in primary care.
Methods/design: This study is a pragmatic cluster randomized controlled trial, conducted in primary care (OPTI-
SCRIPT trial), involving 22 practices (clusters) and 220 patients. Practices will be allocated to intervention or control
arms using minimization, with intervention participants receiving a complex multifaceted intervention incorporating
academic detailing, medicines review with web-based pharmaceutical treatment algorithms that provide
recommended alternative treatment options, and tailored patient information leaflets. Control practices will deliver
usual care and receive simple patient-level feedback on potentially inappropriate prescribing. Routinely collected
national prescribing data will also be analyzed for nonparticipating practices, acting as a contemporary national
control. The primary outcomes are the proportion of participant patients with potentially inappropriate prescribing
and the mean number of potentially inappropriate prescriptions per patient. In addition, economic and qualitative
evaluations will be conducted.
Discussion: This study will establish the effectiveness of a multifaceted intervention in reducing potentially
inappropriate prescribing in older people in Irish primary care that is generalizable to countries with similar
prescribing challenges.
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Background
Prescribing in older people
Older people are among the biggest consumers of
healthcare services, particularly drug therapy [1]. They
tend to have multiple conditions, requiring multiple
drug treatments [2]. They also experience age-related
changes in physiology and body composition that influ-
ence the body’s ability to process medications efficiently,
in terms of both pharmacokinetics (the body’s ability to
absorb, distribute, metabolize and excrete a drug) and
pharmacodynamics (the drug’s physiological effects)
[3,4]. Thus, prescribing for older people is a complex
and challenging task, with the potential for adverse out-
comes including drug-drug interactions, adverse drug re-
actions and potentially inappropriate prescribing (PIP)
[5].
The term ‘potentially inappropriate prescribing’ covers
a number of suboptimal prescribing practices, particu-
larly the use of medicines that introduce a greater risk of
adverse drug-related events where a safer and equally ef-
fective alternative is available to treat the same condition
[6]. Inappropriate prescribing in older people can result
in increased morbidity, adverse drug events, hospitaliza-
tions and mortality [7-9]. Potentially inappropriate pre-
scribing may be measured with explicit (criterion-based)
or implicit (judgment-based) tools [9]. A recently devel-
oped explicit process measure, the Screening Tool of
Older People’s Prescriptions (STOPP), has been pub-
lished for use in European settings [10].
When these criteria were applied to an Irish pharmacy
claims database (containing the prescription records of
97% of those aged ≥70 nationally), it was found that 36%
of those aged ≥70 years received at least one potentially
inappropriate medication. Total PIP expenditure was es-
timated at over €45 million (or 9% of expenditure on
pharmaceuticals in that age group) [11]. The clinical and
economic burden of PIP is an important public health
concern and it is important to minimize PIP where pos-
sible, to increase patient safety and encourage cost-
effective prescribing.
Interventions to change prescribing
Changing professional practice is a complex and difficult
task. While the usefulness of behaviour change theory in
intervention and implementation research has been
questioned, [12,13] there is general consensus that inter-
ventions are more likely to have an impact when they
target all stages of behaviour change [14]. Studies to date
have yielded mixed results in terms of which interven-
tion types are most effective in improving prescribing
and there is no one interventional strategy that has
proved to be most effective [15]. Strategies shown to be
effective for improving prescribing outcomes include
educational outreach visits (academic detailing) [16] and
interventions involving a pharmacist [17]. Pharmacist
services, such as conducting medicines reviews or pro-
viding advice to general practitioners (GPs) may lead to
improvements in prescribing outcomes, including more
appropriate prescribing in older people [9,17-21].
Patient-mediated interventions do not consistently show
effects in improving prescribing [22]; however, evidence
suggests that providing patients with information is im-
portant. Patient information leaflets may be helpful in
improving patient outcomes, and older people appreci-
ate receiving brief, clearly written information leaflets
[23,24]. A number of commentators have argued that a
multifaceted intervention, an approach that combines a
number of techniques within a single intervention [20],
may be more likely to work than any one single inter-
vention [9,25,26].
Study aim and objectives
The aim of this study is to determine the effectiveness
and acceptability of a complex, multifaceted intervention
in reducing the level of PIP in primary care. The inter-
vention combines academic detailing, medicines review
with web-based pharmaceutical treatment algorithms
that provide recommended alternative treatment op-
tions, and tailored patient information leaflets. The
intervention development was informed by the Medical
Research Council (MRC) guidelines for the development
and evaluation of randomized controlled trials (RCTs)
[27,28]. It was piloted with a group of five GPs and
found to be feasible and acceptable within this group.
Secondary objectives are to evaluate the effect of the
intervention on patient outcomes in terms of the num-
ber of GP visits, the number of hospitalizations, patient
well-being, beliefs about medicines and health status.
The views and experiences of participants concerning
the possible reasons for the intervention to be effective
or ineffective will be explored using qualitative method-
ology. In addition, an economic evaluation will be car-
ried out.
Methods/design
Trial design
The OPTI-SCRIPT study is a pragmatic two-arm cluster
RCT, incorporating qualitative analysis. Qualitative ap-
proaches can contribute in several ways to the develop-
ment and evaluation of health interventions; they have
been used during intervention development and piloting
and will be used to undertake a process evaluation of
the trial [29]. The study design was developed in line
with the Consolidated Standards of Reporting Trials
(CONSORT) statement extension to cluster RCTs [30].
A cluster design was chosen to avoid the possibility of
contamination across arms. A GP who is treating both
intervention and control patients might find it difficult
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Figure 1 Flow of practices and patients through RCT.
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to behave differently towards each group [31]. The trial
will be conducted in primary care with GP practices as
the unit of randomization. A practice can be a single-
handed GP or can comprise two or more GPs (group
practices); however, not all GPs in group practices may
wish to participate. Participation may be decided by one
GP on behalf of the group practice, in which case that
GP will be the main point of contact for the study. We
will keep a record of participating GPs. Participation in
the intervention arm will be defined as attendance at the
academic detailing visit and undertaking medicines re-
views, while participation in the control group as provid-
ing patient prescription data. Practices that do not meet
these criteria will be considered lost to follow-up (see
Figure 1). The intervention will be delivered at the GP
level while the unit of analysis will be at the individual
patient level, in terms of medicines prescribed, adjusting
for clustering.
Study population
Practices are eligible to participate if they have approxi-
mately 80 or more older patients (aged ≥70 years) on
their patient panel (based on the need to recruit 10 pa-
tients per practice, and allowing for refusals) and they
are based in the greater Dublin area (to facilitate the aca-
demic detailing process).
Practices are excluded where they have been involved
in the development and piloting of the intervention or
other concurrent medication quality related studies.
Patients will be considered eligible if they are aged 70 -
years or over and they are being prescribed one or more
selected potentially inappropriate prescriptions on a re-
peat basis (only patients with an existing PIP will be in-
cluded, as the intervention is specifically targeting the
management of PIP).
Patients will be excluded if they have significant men-
tal or physical illness that is likely to impair their ability
to participate in the study, or they are unable to attend
the GP surgery for consultation (for example, they are
nursing home residents) or they are participating in an-
other medication quality related study.
Recruitment and allocation
Potentially eligible practices (based in the greater Dublin
area) will be identified from the Health Research Board
(HRB) Primary Care Research Centre research network.
All eligible practices will be invited to participate by an
email (or letter where email address is unavailable),
Table 1 Intervention components
Intervention component Description
Academic detailing A research pharmacist will visit the intervention practices. During the academic detailing, the
pharmacist will:
• Discuss the concept of PIP with the GPs, focusing on the prevalence and consequences of PIP in
primary care
• Discuss the pharmaceutical treatment algorithm
• Discuss the medicines review process
• Demonstrate the web-based platform for accessing the pharmaceutical treatment algorithm for
use in a medicines review with each participant patient
Medicines review with web-based
pharmaceutical treatment algorithms
GPs will be asked to:
• Schedule a medicines review for the patient’s next appointment
• Log on to the designated website using individualized user-names and passwords
• Access the individualized web-based pharmaceutical treatment algorithms for each patient
during the review
• Conduct a medicines review following the page-by-page web-based pharmaceutical treatment
algorithms. Each pharmaceutical treatment algorithm has the following structure:
Section A: The individual PIP with reason for concern
Section B: Alternative pharmacological and nonpharmacological treatment options
Section C: Background information (where relevant)
• Complete the process by submitting the review outcome form for each PIP per patient
Each GP will also be provided with a full, paper-based compendium of pharmaceutical treatment
algorithms for reference
Patient information leaflets For every alternative therapy option, a brief patient information leaflet has been written. These
leaflets describe the PIP and the reasons why it may be inappropriate. They also outline the
alternative therapies the GP may offer instead
Note: The decision on whether to follow the recommended treatment alternatives will be at the discretion of the GP, weighing up the risks and benefits and
patient preference.
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Table 2 Selected prescribing criteria and indicators
Criterion Concern Prevalence
in Ireland*
PPI for peptic ulcer disease at full therapeutic dosage for >8 weeks Earlier discontinuation or dose reduction for maintenance or
prophylactic treatment of peptic ulcer disease, oesophagitis or
GORD is indicated
16.69% [11]
7.68% [49]
4.06% [10]
NSAID (>3 months) for relief of mild joint pain in osteoarthritis Simple analgesics are preferable and usually as effective for pain
relief
8.76% [11]
1.05% [49]
1.26% [10]
Long-term (>1 month), long-acting benzodiazepines, for example,
chlordiazepoxide, flurazepam, nitrazepam and clorazepate, and
benzodiazepines with long-acting metabolites, for example,
diazepam
Risk of prolonged sedation, confusion, impaired balance, falls 5.22% [11]
5.19% [49]
3.00% [49]
6.01% [10]
9.09% [10]
Any regular duplicate drug class prescription, for example, two
concurrent opiates, NSAIDs, SSRIs, loop diuretics, ACE inhibitors.
Excludes duplicate prescribing of drugs that may be required on a
p.r.n. basis, for example, inhaled β2 agonists (long and short acting)
for asthma or COPD, and opiates for management of breakthrough
pain
Optimization of monotherapy within a single drug class should
be observed prior to considering a new class of drug
4.78% [11]
2.18% [49]
6.01% [10]
TCAs with an opiate or calcium channel blocker Risk of severe constipation 2.05% [11]
0.37% [49]
Aspirin at dosage >150 mg/day Increased bleeding risk, no evidence for increased efficacy 1.69% [11]
0.3% [49]
0.14% [10]
Theophylline as monotherapy for COPD or asthma Risk of adverse effects due to narrow therapeutic index 1.18% [11]
0.56% [10]
Use of aspirin and warfarin in combination without histamine H2
receptor antagonist (except cimetidine because of interaction with
warfarin) or PPI
High risk of GI bleeding 1.09% [11]
0.3% [49]
Doses of short-acting benzodiazepines, doses greater than:
lorazepam (AtivanW), 3 mg; oxazepam (SeraxW), 60 mg; alprazolam
(XanaxW), 2 mg; temazepam (RestorilW), 15 mg; and triazolam
(HalcionW), 0.25 mg
Total daily doses should rarely exceed the suggested maximums 0.98% [49]
1.54% [10]
Prolonged use (>1 week) of first-generation antihistamines, that is,
diphenhydramine, chlorpheniramine, cyclizine, promethazine
Risk of sedation and anticholinergic side-effects 0.96% [11]
0.15% [49]
Warfarin and NSAID together Risk of GI bleeding 0.75% [11]
1.68% [10]
Calcium channel blockers with chronic constipation May exacerbate constipation 0.68% [49]
0.28% [10]
NSAID with history of peptic ulcer disease or GI bleeding, unless
with concurrent histamine H2 receptor antagonist, PPI or
misoprostol
Risk of peptic ulcer relapse 0.67% [49]
0.42% [10]
Bladder antimuscarinic drugs with dementia Risk of increased confusion, agitation 0.46% [11]
0.84% [10]
TCAs with constipation May worsen constipation 0.45% [49]
0.14% [10]
Digoxin at a long-term dosage >125 μg/day (with impaired renal
function)
Increased risk of toxicity 0.36% [11]
0.15% [49]
0.55% [10]
Thiazide diuretic with a history of gout May exacerbate gout 0.36% [11]
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which will include a study information leaflet outlining
steps of the intervention and availability of continuing
medical education (CME) points for participation. When
a practice agrees to participate, a member of staff (for
example, a GP, practice manager or nurse) will be se-
lected by the practice. The research team will instruct
the designated person on how to identify a random sam-
ple of 50 patients aged 70 years and over from the pa-
tients of participating GPs within the practice. They will
pseudo-anonymize the records by assigning the patients
a study ID and send a copy of the pseudo-anonymized
prescription records to the research team, where a re-
search pharmacist will generate a list of potentially eli-
gible patients, that is, patients with PIP. A maximum of
ten patients per practice is required; if more than ten pa-
tients are identified, ten patients will be selected at
random from the list of eligible patients. Eligible patients
will be sent a letter of invitation, a patient information
leaflet and a consent form, asking them to participate
and answer a questionnaire. Prior to practice allocation,
baseline patient data (including prescription data,
process-of-care measures and patient-reported outcomes
– see sections on outcomes and data collection) will be
collected. Practices will then be assigned to intervention
or control using minimization. This approach offers the
advantage of ensuring balance between the groups [32]
in terms of prognostic factors: in this case, practice size
(number of whole-time-equivalent GPs) and practice lo-
cation (urban or rural, where an urban area is defined as
a relatively small centre of population, with 5000 or
more residents [33]). A chart of the flow of participants
through the study is presented in Figure 1. Because of
Table 2 Selected prescribing criteria and indicators (Continued)
0.45% [49]
0.14% [10]
Glibenclamide (with type 2 diabetes mellitus) Risk of prolonged hypoglycaemia 0.29% [11]
0.22% [49]
Aspirin with a past history of peptic ulcer disease, without histamine
H2 receptor antagonist or PPI
Risk of bleeding 0.22% [49]
0.28% [10]
Prochlorperazine (StemetilW) or metoclopramide with parkinsonism Risk of exacerbating parkinsonism 0.21% [11]
TCAs with dementia Risk of worsening cognitive impairment 0.18% [11]
0.28% [10]
TCAs with glaucoma Likely to exacerbate glaucoma 0.14% [11]
0.07% [49]
TCAs with cardiac conductive abnormalities Pro-arrhythmic effects 0.14% [10]
Long-term corticosteroids (>3 months) as monotherapy for
rheumatoid arthritis or osteoarthritis
Risk of major systemic corticosteroid side-effects 0.14% [10]
Bladder antimuscarinic drugs with chronic prostatism Risk of urinary retention 0.14% [10]
NSAID with heart failure Risk of exacerbation of heart failure 0.07% [49]
0.14% [10]
TCAs with prostatism or prior history of urinary retention Risk of urinary retention 0.07% [49]
0.14% [10]
Systemic corticosteroids instead of inhaled corticosteroids for
maintenance therapy in COPD or asthma
Unnecessary exposure to long-term side-effects of systemic
steroids
0.07% [49]
0.56% [10]
Bladder antimuscarinic drugs with chronic glaucoma Risk of acute exacerbation of glaucoma <0.01% [11]
NSAID with SSRI Increased risk of GI bleeding N/A
Bladder antimuscarinic drugs with chronic constipation Risk of exacerbation of constipation N/A
Prednisolone (or equivalent) > 3 months or longer without
bisphosphonate
Increased risk of fracture N/A
NSAID with ACE-inhibitor Risk of kidney failure, particularly with the presence of general
arteriosclerosis, dehydration or concurrent use of diuretics
N/A
NSAID with diuretic May reduce the effect of diuretics and worsen existing heart
failure
N/A
ACEI, angiotensin-converting-enzyme inhibitor; COPD, chronic obstructive pulmonary disease; GI, gastro-intestinal; GORD, gastro-oesophageal reflux disease; N/A,
not available; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitor; p.r.n., pro re nata, as needed; SSRI, selective serotonin reuptake inhibitor;
TCA, tricyclic anti-depressant. *Prevalence: the proportion of the study population with one or more potentially inappropriate medications.
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the nature of the intervention, it is not possible to blind
GPs or participants to the intervention.
Intervention
The intervention consists of academic detailing, medi-
cines review with web-based pharmaceutical treatment
algorithms and tailored patient information leaflets. The
academic detailing will involve a research pharmacist
visiting intervention GPs in their own practices. The
visit will include a short educational presentation about
PIP as a concept, the criteria used to measure it and a
summary of studies conducted in Irish primary care on
the topic, as knowledge of PIP may be a barrier to ap-
propriate prescribing in older patients [34]. Subsequent
to this, practices will be asked to complete ten medicines
reviews within a 6 to 8 week period, with a reminder is-
sued if they are not completed within that period. An
extended period may be negotiated, should a practice re-
quire it. During the medicines review, the GPs will use
web-based treatment algorithms specifically designed for
this study and accessible using a link and designated
password. The algorithm will guide the process from the
GP perspective, and does not incorporate patient in-
volvement. It has a page-by-page structure, which will
be completed when the GP fills in a review outcome
form, detailing decisions made by the GP and patient to-
gether, including the reasons for maintaining a PIP,
which is a key element of this study. Once the review
outcome form has been filled in, the medicines review is
complete. The medicines review will take place in the
GP practice and will be scheduled at a date and time
that is convenient to both the GP and the patient. In
group practices where more than one GP is participat-
ing, the reviews may be divided between them in a man-
ner that is most suitable to the practice workload. The
pilot study indicated that the preparation for the review
might be more time consuming for the GP than usual
but there was no indication that the consultation itself
would be significantly longer. These components are
presented in Table 1.
Control group: usual care with simple feedback
The control-group GPs will continue to provide usual
care but will also be provided with simple feedback. Data
for patients in the control group will be reviewed during
recruitment and a personalized patient list for the ten
recruited patients will be given to the GP. The list will
summarize the medication class to which the individual
patient’s potentially inappropriate medication belongs,
not the specific PIP and will not provide actionable rec-
ommendations for change. Participants will not receive
an academic detailing visit, will not be prompted to
carry out a medicines review with the individual pa-
tients, and will not have access to the pharmaceutical
treatment algorithms with alternative therapy options.
GPs will continue to provide usual care. In terms of re-
peat prescribing for public general medical services
(GMS) patients, this means that a GP can give a pre-
scription on a monthly basis or for a maximum of three
months. At present, the Health Service Executive Pri-
mary Care Reimbursement Services (HSE-PCRS) has an
on-line GP Application Suite where GPs can review ad-
ministrative information on their GMS patient panel.
They can also access prescribing analysis reports, which
Table 3 Secondary outcome measures
Secondary outcome Measure
Drug-specific
outcomes
The absolute number of PIPs per patient of the top five occurring PIP drugs: [11]
Proton pump inhibitor (PPI) for peptic ulcer disease at full therapeutic dosage for >8 weeks
Long-term (>3 months) use of NSAIDs for relief of mild joint pain in osteoarthritis
Long-term (>1 month) use of long-acting benzodiazepines, for example, chlordiazepoxide, flurazepam, nitrazepam,
chlorazepate and benzodiazepines with long-acting metabolites for example, diazepam
Any regular duplicate drug class prescription
TCAs with an opiate or calcium channel blocker
Mean number of PIPs per patient of the top five PIP drugs (as above)
Patient-reported
outcomes
Health status (EQ-5D)
Patients’ Beliefs about Medicine Questionnaire (BMQ)
Well-being Questionnaire (WBQ-12)
Process-of-care
measures
Number of GP visits (6 months prior to enrolment and at 4 and 12 month follow-up)
Number of hospital admissions (6 months prior to enrolment and at 4 and 12 month follow-up
Process evaluations Decisions made per PIP
Number of times alternatives were prescribed
Reported primary reason for decision made for example, risks outweigh benefits, patient preference, hospital/consultant
initiated
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contain detailed financial and cost information related to
their prescribing. Specific prescribing alerts and recom-
mendations for older patients are not provided.
Contemporaneous national control HSE-PCRS dataset
The control arm will receive simple feedback about their
patients based on baseline data collection. Feedback has
been found to promote slight improvements in profes-
sional practice but is most effective when it is provided
intensively [35,36]. By participating in this research, the
control group might also alter their behaviour, resulting
in changes in prescribing patterns (that is, the possible
Hawthorne effect). To address this, we will also analyze
national prescription patterns for all GMS doctors via
the HSE-PCRS prescription database after the trial. This
is a national prescribing database based on GP and phar-
macy claims in a number of community schemes, in-
cluding the GMS scheme. Data from the PCRS GMS
database can be used to compare practices participating
in the study with nonparticipating practices, acting as a
contemporary national control. Some 330,000 people
aged 70 and over were eligible for the GMS scheme in
2009 [37]. Comparisons with previous PIP patterns na-
tionally [11] will determine whether there have been
changes over time at the population level.
Outcome measures
The study focuses on a select number of PIP criteria
identified in the literature that have been determined to
be of clinical relevance by academic GPs and pharma-
cists, and are prevalent in Irish primary care (see
Table 2).
The primary outcomes to be determined are the pro-
portion of participant patients with PIP (as a composite
measure, that is, any number of PIP criteria as listed in
Table 2, to address the issue of multiple PIP in individual
patients) and the mean number of potentially inappro-
priate prescriptions per patient.
Secondary outcomes (summarized in Table 3) will in-
clude individual measures of the composite measure,
that is, drug-specific outcomes, process evaluations,
process-of-care measures and patient-reported outcomes
(Health status (EQ-5D) [38], Patients’ Beliefs about
Medicine Questionnaire (BMQ) [39], Well-being Ques-
tionnaire (WBQ-12) [40]).
Data collection
Prescription data, process-of-care measures and patient-
reported outcomes will be collected at baseline and on
intervention completion, that is, the point at which all
ten reviews have been completed (this must be within a
6 to 8 week period). Follow-up data will also be collected
12 months after the intervention completion. Data will
be collected from the following sources:
GP medical chart
Patient records will be used to collect the drug-specific
outcome data for all participants at baseline and
follow-up. Process-of-care data, such as health-service
utilization (for example, the number of GP visits) will
also be collected for intervention and control patients.
Questionnaire
Patient-reported outcomes for intervention and control
will come from questionnaire data, which will be col-
lected at baseline and follow-up, using a postal question-
naire and telephone follow-up for nonresponders. The
questionnaire will be used to collect personal and demo-
graphic data, economic data, and health-service
utilization data along with data from the EQ-5D, BMQ
and WBQ-12.
Evaluation data
Process-measure data for the intervention group will be
collected by outcome forms completed by GPs at the
end of each of the ten medicines reviews they conduct
for the ten recruited patients. In single-handed practices,
the same GP will conduct the reviews and complete the
outcome forms. In group practices, where more than
one GP is participating in the study, the reviews may ei-
ther be conducted by an individual GP nominated by
the practice or be shared between the GPs, with GPs
completing outcome forms for the patients they
reviewed. Semistructured qualitative interviews will also
be conducted with both GPs and patients after the inter-
vention, to evaluate the intervention (see below for more
detail). GPs in the control arm will also be interviewed,
to ascertain any potential impact of the feedback they re-
ceive, based on the baseline data.
Plan of analysis
The minimization process will ensure balance between
treatment groups in terms of certain prognostic factors.
Descriptive statistics will be used to evaluate differences
in other baseline characteristics between participating
physicians and patients in the two arms of the trial. The
primary analysis will be carried out using multilevel
modeling (such as mixed linear effects modeling or gen-
eralized estimating equations [41]) to control for the ef-
fects of clustering and baseline differences. All analysis
will be conducted under the intention-to-treat principle.
Subgroup analyses will be performed for the primary
outcome to assess whether the intervention varies by
practice size or GP characteristics, such as sex or num-
ber of PIP drugs. As this is a pragmatic trial, a second-
ary, per-protocol analysis will also be conducted. This
form of analysis includes only those participants who
completed the treatment protocol originally allocated,
providing results on the efficacy of the trial [42].
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Sample size
As all the patients in this study will be selected on the
basis of already having one or more potentially inappro-
priate prescriptions, the sample size calculations are
based on a 100% prevalence rate. Separate sample size
calculations were performed for the two primary
outcomes:
Proportion of participant patients with PIP
The calculation is based on demonstrating a clinically
relevant 10% absolute reduction (from 100% to 90%) in
the proportion of PIP with 80% power and a statistical
significance of 5% (one-sided), between the randomized
groups. With a cluster design, the assumption that indi-
vidual outcomes are independent of each other does not
hold, as participants in the same cluster may respond in
the same way. The sample size, therefore, needs to be
adjusted to reflect this by use of the intraclass correl-
ation coefficient (ICC) [43]. We used an ICC of 0.025,
based on an ongoing unpublished observational study of
an elderly cohort in the HRB Centre for Primary Care
Research. With a maximum of ten patients per cluster
and factoring in a loss to follow-up of 10%, a total of 22
GP practices and 212 patients will be required.
Mean number of PIP per patient
An ongoing unpublished observational study of an eld-
erly cohort in the HRB Centre for Primary Care Re-
search estimates a mean number of 1.45 inappropriate
prescriptions per patient. To demonstrate a 30% relative
reduction in the mean number of PIP (equivalent to a
mean of 1.02), with 80% power and a statistical signifi-
cance of 5% (two-sided), between the randomized
groups, with a maximum of ten patients per cluster and
factoring in a loss to follow-up of 10%, a total of 14 GP
practices and 132 patients will be required.
These calculations indicate that we would need at least
22 practices and 212 patients to detect a difference be-
tween the intervention and control arms for both of our
primary outcome measures. On the basis of these calcu-
lations, we aim to recruit at least 22 practices, with 10
patients per practice, giving a total of 220 patients. With
this sample size, we would have at least 80% power to
demonstrate a 10% absolute reduction in the proportion
of PIP and a 30% relative reduction in the mean number
of PIPs. Based on existing evidence that suggests that
simple, less intensive feedback does not alter prescribing
behaviour [35,36] we have not anticipated an improve-
ment in the control arm. However, we will monitor for
this in the parallel process evaluation.
Data management and protection
A trial steering committee will be established. The aim
of the trial is to identify older patients with existing PIP.
These patients will be known to the research team by
study ID number only. One member of the research
team (BC) will have access to patient contact details for
follow-up data collection purposes. The GP remains re-
sponsible for all treatment decisions made. Informed
consent will be sought from all study participants. All
data collected will be stored on a secure, password-
protected server. All interviews will be audio recorded
and transcribed, the digital recording overwritten and
the transcripts pseudo-anonymized and stored on a se-
cure, password-protected server.
The academic detailing will demonstrate the process
of the medicines review with the intervention practices
but the research team will not monitor how the GP im-
plements the study protocol after this, other than to re-
mind the practices to complete the process within the
allotted period. This study is pragmatic in nature, meas-
uring the intervention’s effectiveness in real clinical
practice.
Ethical approval
Ethical approval was granted by the Research Ethics
Committee of the Irish College of General Practitioners
(ICGP). At the request of the Ethics Committee, some
changes were made to the study protocol. The patient
information letter and questionnaire were rewritten to
be clearer and simpler for an older audience. Initially, it
was proposed that a member of the research team (BC)
would become a research agent of the practice, in order
to minimize the effort required by the practice staff to
recruit patients [44]. However, the ethics committee re-
quested that the practices should be responsible for the
patient consent process. The committee also requested
that any prescribing pattern of concern identified by the
research team should be referred to an external aca-
demic GP with no involvement in the trial to assess the
case and to determine the necessary next steps; this ar-
rangement has been put in place.
Qualitative evaluation
A qualitative process evaluation will be conducted to ex-
plore participant attitudes towards the intervention and
the experience of the intervention delivery. Specifically,
semistructured interviews will be conducted with a sam-
ple of participants, both GPs and patients, from the
intervention arm. The interviews will be structured
using a topic guide, which will be developed with the
stages of the interview in mind (introducing the re-
search, beginning the interview, and so on) [45]. These
interviews will address such research questions as:
1. What are the views of the participants about the
acceptability, effectiveness and sustainability of the
intervention?
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2. What barriers, if any, were experienced by GPs in
relation to implementing the alternative
recommended treatments?
3. How did patients respond or react to the idea of
altering their medication regimes?
4. Was the medicines review viewed as a useful
exercise for the patient or the GP, or both?
5. In what ways might the intervention be modified or
adapted to maximize its effectiveness in routine care?
A random sample of participants in the intervention
arm will be invited to participate. The number of inter-
views required to reach data saturation (where no new
themes emerge) will be considered, alongside feasibility
issues (resources and timing), but a sample of 10 to 15
patients and 10 GPs is proposed [46]. For individual pa-
tients, the interviews will take place within one month
of the medicines review. For GPs, the interviews will be
conducted within one month of them completing their
assigned reviews, that is, after all ten reviews for single-
handed practices and after completion of assigned reviews
in group practices. The interviews will be conducted either
in person (in a setting of the participant’s preference) or
via telephone. Telephone interviewing is generally used in
qualitative research where time or cost is an issue and
there is evidence that there is little difference in the an-
swers obtained this way [47]. In this case, scheduling face-
to-face interview time with GPs and older patients may be
difficult, so telephone interviewing is an option. In
addition, as part of the process evaluation, we will conduct
brief telephone interviews with the control-group GPs to
ascertain any potential impact of the feedback they receive
based on the baseline data. Control-group participants will
not be required to document any of the decisions made
with regard to the control data, so this approach may be
more prone to recall bias. However, we consider it a suit-
able option, given the limited time available in busy GP
practices. All interviews will be audio recorded (on loud-
speaker for telephone interviews) and transcribed. The
data will be collated and a thematic analysis will be
conducted. There are four main steps to conducting a the-
matic analysis:
1. Collect the data.
2. Identify patterns and themes (repetition).
3. Collate related patterns into subthemes.
4. Interpret themes in light of a literature review [48].
NVivo 9 will be used to assist with organizing the data
for analysis.
Economic evaluation
A health economic analysis will be conducted following
the RCT to explore the direct costs of the intervention
and link these to its potential effectiveness. We will
compare the direct costs of delivering the OPTI-SCRIPT
intervention as an alternative to usual care. Economic
analysis is particularly important in relation to quality of
prescribing, owing to the considerable costs invested by
healthcare systems in medicines and their prescribing.
There are potential cost savings from reducing doses
and quantities of inappropriately prescribed medications,
and from reducing potential adverse events associated
with suboptimal prescribing. There is also potential for
cost increases if the appropriate alternative medicine
recommended is more expensive. Therefore, it will be
important to determine the cost/benefit ratios for any
changes made in medicines prescribed as a result of the
intervention.
Cost-effectiveness analysis will be undertaken, in
which effectiveness will be measured in terms of the re-
duction in the proportion of potentially inappropriate
prescriptions. Direct-cost data will be calculated for all
the health resources consumed. All contacts with the
health service will be recorded and valued, including GP
visits, hospital attendances, hospital admissions and drug
prescriptions.
Discussion
Prescribing for older patients is a complex and challen-
ging task. The literature to date demonstrates that high
levels of PIP exist among older people in Ireland [49].
This creates an increased clinical and economic burden
with an impact on other patient outcomes, such as in-
creased hospitalizations and mortality. As the proportion
of older patients in the population increases and the ne-
cessity for pharmaceutical therapy intensifies, it is crucial
to find ways to ensure the safety and quality of prescrib-
ing in primary care. Currently, no one interventional
strategy has proven to be the most effective in address-
ing PIP. This study is seeking to determine the effective-
ness of a complex, multifaceted intervention in reducing
the level of PIP in primary care.
The use of the MRC guidelines for the design and
evaluation of complex interventions is a strength of this
study. The study is innovative in that focuses on a num-
ber of PIP criteria that have been determined to be of
clinical relevance and high prevalence by academic GPs
and pharmacists, rather than applying all criteria from a
specific list. Clinically relevant alternatives have also
been provided, ensuring that where PIP has been
highlighted, actionable recommendations have been
made available to the prescriber.
There are some practical limitations to the OPTI-
SCRIPT intervention. The identification of PIP in pa-
tients could be carried out by a pharmacist who could
apply the criteria to patient records but this would re-
quire a formalization of the role of the pharmacist
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within the GP team to enable access to patient records,
affecting both cost and service delivery. There are also
implications for data protection when a person external
to a practice, such as a pharmacist, requires access to
patient records. This process could, ideally, be auto-
mated, and incorporated into the workflow of the vari-
ous practice-management software systems used in
primary care, along with the treatment algorithms. How-
ever, as with all computerized prompts, this would have
to be carefully designed to avoid the danger of ‘alert fa-
tigue’, which could become an issue. In addition, a medi-
cines review process is not standard practice in Irish
primary care as it is in other countries, such as the UK,
where the National Service Framework for older people
recommends that all people over the age of 75 should
have their medicines reviewed at least once a year [50].
Were such a process to be introduced in Ireland, an
agreement would have to be made about reimbursement
mechanisms. The majority of people aged 70 and over in
Ireland are entitled to free, state-funded GP care and
medications (public patients). A small minority of this
age group are private patients (approximately 5%), and
therefore pay for their own medical care. If a medicines
review process were to be introduced into standard care,
an agreement would have to be reached as to whether it
would be entirely state-funded or whether private pa-
tients would have to incur the costs of such a service
personally. Should the OPTI-SCRIPT intervention be
found to be effective, these issues would need to be
taken into consideration prior to its implementation into
routine care. In summary, with a growing population of
older people, this study will provide evidence concerning
the suitability of implementing such an intervention in
the Irish Primary Care Sector for older populations.
Trial status
At the time of submission of this article, 22 GP practices
had been recruited. Patient identification and recruit-
ment was just commencing.
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